| __timestamp | Opthea Limited | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3401685 | 7459000 |
| Thursday, January 1, 2015 | 4284228 | 11831000 |
| Friday, January 1, 2016 | 3581295 | 25705000 |
| Sunday, January 1, 2017 | 4838300 | 46181000 |
| Monday, January 1, 2018 | 24891534 | 59497000 |
| Tuesday, January 1, 2019 | 31347891 | 65003000 |
| Wednesday, January 1, 2020 | 17480747 | 74506000 |
| Friday, January 1, 2021 | 34710152 | 126006000 |
| Saturday, January 1, 2022 | 108459978 | 126215000 |
| Sunday, January 1, 2023 | 181563523 | 120161000 |
| Monday, January 1, 2024 | 176326321 |
Igniting the spark of knowledge
In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Opthea Limited and Protagonist Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D investments. From 2014 to 2023, Opthea Limited's R&D expenses surged by over 5,200%, peaking in 2023. In contrast, Protagonist Therapeutics, Inc. showed a steady increase, with a notable 1,500% rise by 2022, before a slight dip in 2023. This divergence highlights Opthea's aggressive push in recent years, while Protagonist maintains a consistent yet cautious approach. The data suggests that Opthea is ramping up efforts to bring groundbreaking therapies to market, whereas Protagonist is strategically pacing its innovation journey. Missing data for 2024 suggests a potential shift or pause in Protagonist's strategy, warranting close observation.
Comparing Innovation Spending: Eli Lilly and Company and Opthea Limited
R&D Insights: How Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for United Therapeutics Corporation and Opthea Limited
Research and Development Investment: Viatris Inc. vs Protagonist Therapeutics, Inc.
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Blueprint Medicines Corporation vs Opthea Limited: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Opthea Limited and CymaBay Therapeutics, Inc.
Analyzing R&D Budgets: Opthea Limited vs Veracyte, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and Protagonist Therapeutics, Inc.
Comparing Innovation Spending: CRISPR Therapeutics AG and Protagonist Therapeutics, Inc.
Research and Development Expenses Breakdown: Veracyte, Inc. vs Protagonist Therapeutics, Inc.
Research and Development Investment: Protagonist Therapeutics, Inc. vs Evotec SE